Difference between revisions of "Juvenile myelomonocytic leukemia"
Jump to navigation
Jump to search
m |
Warner-admin (talk | contribs) m (Text replacement - "|Years of enrollment" to "|Dates of enrollment") |
||
Line 18: | Line 18: | ||
{| class="wikitable sortable" style="width: 60%; text-align:center;" | {| class="wikitable sortable" style="width: 60%; text-align:center;" | ||
!style="width: 33%"|Study | !style="width: 33%"|Study | ||
− | !style="width: 33%"| | + | !style="width: 33%"|Dates of enrollment |
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]] | !style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
|- | |- |
Revision as of 18:40, 25 March 2023
1 regimens on this page
1 variants on this page
|
First-line therapy
Azacitidine monotherapy
Regimen
Study | Dates of enrollment | Evidence |
---|---|---|
Niemeyer et al. 2021 (AZA-JMML-001) | 2015-2017 | Phase 2, <20 pts (RT) |
References
- AZA-JMML-001: Niemeyer CM, Flotho C, Lipka DB, Starý J, Rössig C, Baruchel A, Klingebiel T, Micalizzi C, Michel G, Nysom K, Rives S, Schmugge Liner M, Zecca M, Schönung M, Baumann I, Nöllke P, Benettaib B, Biserna N, Poon J, Simcock M, Patturajan M, Menezes D, Gaudy A, van den Heuvel-Eibrink MM, Locatelli F. Response to upfront azacitidine in juvenile myelomonocytic leukemia in the AZA-JMML-001 trial. Blood Adv. 2021 Jul 27;5(14):2901-2908. link to original article link to PMC article PubMed NCT02447666